Infusion of low dose of vasopressin versus phenylephrine for prevention of cardiopulmonary bypass induced vasoplegic syndrome in patients undergoing coronary artery bypass grafting surgery

Infusion of low dose of vasopressin versus phenylephrine for prevention of cardiopulmonary bypass induced vasoplegic syndrome in patients undergoing

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201408201127N2

Enrollment

Registered

2014-10-18

Start date

2014-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiopulmonary bypass induced vasoplegic shock. Diseases of arteries, arterioles and capillaries

Interventions

Intervention 1: Intervention group1: Starting infusion of vasopressin (Exir pharmaceutical co. Iran) 0.1 IU/min with starting of cardiopulmonary bypass and continuing it up to 4 hours after weaning f

Treatment - Drugs

Placebo

Intervention group1: Starting infusion of vasopressin (Exir pharmaceutical co. Iran) 0.1 IU/min with starting of cardiopulmonary bypass and continuing it up to 4 hours after weaning from cardiopulmon

Intervention group2: Starting infusion of phenylephrine (West-ward Pharmaceutical Corp. USA) 0.1 µg/kg/min (prepared as 5 mg in 50 ml normal saline) with starting of cardiopulmonary bypass and continu

Placebo group: Starting NaCl 0.9% Infusion (2 ml/h) with starting of cardiopulmonary bypass and continuing it up to 4 hours after weaning from cardiopulmonary bypass.

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients 18 up to 70 years olds who are candidate for elective cardiac surgery using cardiopulmonary bypass Exclusion Criteria: Urgent Surgery; Surgery without cardiopulmonary bypass; Diabetes mellitus; Respiratory, hepatic or renal disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of post operative vasoplegic shock. Timepoint: post cardiopulmonary bypass and post operative period. Method of measurement: Needs to vasoactive drugs.	—

Secondary

Measure	Time frame
Post operative complications. Timepoint: Post operatively in intensive care unite. Method of measurement: Clinical evaluation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHassan Soleiman Pour

Medicine faculty, Tabriz University of Medical Sciences

soleimanpourh@tbzmed.ac.ir+98 41 3336 4667

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026